Beyond Then Ninety Minutes

Globe Life Inc. (NYSE: GL) reported that for the quarter ended September 30, 2022, net income was $1.90 per diluted common share, compared with $1.84 per diluted common share for the year-ago quarter. Net operating income for the quarter was $2.15 per diluted common share, compared with $1.78 per diluted common share for the year-ago quarter. HIGHLIGHTS: Net income as an ROE was 11.2% for […]

Those who actively choose to save for retirement via so-called sustainable funds are not only driven by values of equality, justice and the environment. They also have a tendency to prioritise authority, and attach less importance to wealth. This is shown by a new study from the University of Gothenburg. Those who work and pay […]

Reference is made to the stock exchange release as of 18 July 2022, where Green Energy Group (SBX, “the Company”) published that it has entered into a binding agreement to sell the “Petrel Explorer” to an undisclosed buyer for an undisclosed sum. The transaction was completed 29 August 2022. The Company has handed over the […]

UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2022. “We are thrilled with the recent data announced in our BEHOLD Study in patients with DME and are grateful for the support and enthusiasm from […]

Applied Materials, Inc. today announced that Dr. Omkaram (Om) Nalamasu, Senior Vice President and Chief Technology Officer, is the recipient of the 2023 IEEE Frederik Philips Award, which honors outstanding accomplishments in the management of research and development resulting in effective innovation in the electrical and electronics industry. Dr. Nalamasu received the award for leadership in […]

Glaston Corporation will disclose the following financial reports in 2023: Financial Statement Bulletin 2022, on Thursday, 9 February 2023 Interim report January-March 2023, on Wednesday, 26 April 2023 Half year financial report January-June 2023, on Tuesday, 1 August 2023 Interim report January-September 2023, on Thursday, 26 October 2023 Glaston’s Financial Statements 2022 and Annual Report 2022 […]

AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the European Union (EU) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm), who have human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.   This approval by […]